chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Got sick after each dose; experienced side effects after each dose; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (Got sick after each dose) and VACCINATION COMPLICATION (experienced side effects after each dose) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 028A21A and 027A21A) for COVID-19 vaccination.     Previously administered products included for Drug use for unknown indication: Seasonal Flu Vaccine (IM) in October 2021. Past adverse reactions to the above products included No adverse event with Seasonal Flu Vaccine. Concurrent medical conditions included Sulfonamide allergy, Allergy to sting and High cholesterol. Concomitant products included ATORVASTATIN CALCIUM (LIPITOR) for an unknown indication.   On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 02-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On 29-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .25 milliliter. On an unknown date, the patient experienced ILLNESS (Got sick after each dose) and VACCINATION COMPLICATION (experienced side effects after each dose). At the time of the report, ILLNESS (Got sick after each dose) and VACCINATION COMPLICATION (experienced side effects after each dose) had resolved.            It was reported that patient has never been diagnosed/tested positive for COVID-19. Treatment medications were not reported.   This case was linked to MOD-2022-537585, MOD-2022-537576, MOD-2022-537582 (Patient Link).
Fever Muscle aches Headaches Nausea (04/10/2021 @ 2000
welts; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (welts) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031220A) for COVID-19 vaccination.     Concurrent medical conditions included Crohn's disease. Concomitant products included USTEKINUMAB (STELARA) for Crohn's disease.   On 17-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to dosage form. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date, the patient experienced URTICARIA (welts). At the time of the report, URTICARIA (welts) outcome was unknown.            Action taken with mRNA-1273 in response to the event was not applicable.   This case was linked to MOD-2021-067731 (Patient Link).
Allergic reaction Rt arm, approx 3" x 5". Taking BENADRYL and icing. Started evening of 2/5 then increased from quarter-size to present.
I woke up with  a nose bleed after 4 days after the shot. I was able get it stop and while at the doctor I caught up a blood clot. Couple days later I still was having a nosebleed. My blood pressure did spike.
Received 1st dose 2/27/21. Fever of 102F started 2/28/21 with chills, resolved with tylenol. Redness at injection site started 2/27/21, then had spread to "the size of 2 half dollars." Not getting any bigger now on 3/2/21. Injection site was itchy too. 2/29/21, fever between 99 and 100.5 and took Tylenol again once getting chills. Suspect that patient had fever in response to COVID vaccine due to previous injection with COVID19 and patient confirmed she had previously had COVID19.
Patient tested positive for Influenza type B. She had not received the influenza vaccine for 2017-18.
Student came to nurses office to say she had rash after vaccine given on 11/5. The child report this to me the day after vaccine - had rash. Mom gave child BENADRYL. I saw her on 11/6 - no reaction.
I was given the Moderna vaccine, 1st dose, just over a week ago.  I've been experiencing extreme fatigue for the past week, and today I discovered red mark and itching at the injection site.  My left arm is sore around the injection site.
heart was shaking/fluttering; heart was shaking/fluttering; extremely exhausted; her chest has bruising; increase of heart rate; This is a spontaneous report from a contactable consumer (parent) received via COVID-19 Adverse Event Self-Reporting Solution . A 17-year-old non-pregnant female patient (reporter's daughter) received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), via an unspecified route of administration, administered in left arm on 04Sep2021 at 10:00 AM (Batch/Lot Number: FC3182) (at the age of 17-years-old) as dose 2, single for COVID-19 immunisation. Vaccine facility type was pharmacy or drugstore. The patient was not pregnant at time of vaccination. Medical history included sickle cell trait and has known allergies to NSAIDS. The patient's concomitant medications were not reported. The patient did not receive any other vaccine in four weeks and did not receive any other medications in two weeks. Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), via an unspecified route of administration, administered in left arm on 14Aug2021 at 03:00 PM (Batch/Lot Number: FA7485) (at the age of 17-years-old) as dose 1, single for COVID-19 immunisation. On 08Sep2021 at 10:45 PM, the patient was complaining that her heart was shaking/fluttering, extremely exhausted, and her chest has bruising. The events resulted in a doctor or other healthcare professional office/clinic visit. The patient was given treatment. Relevant test included electrocardiogram (EKG) with unknown results. The patient was now being monitored for increase of heart rate and what she's doing at the time. The patient has no COVID-19 prior to vaccination and has not been tested for COVID-19 post vaccination. The outcome of the event was not recovered.  No follow-up attempts are needed. No further information is expected.
Pt had a near syncopal episode where she became lethargic and nauseated at 1200.  Pt became pale and diaphoretic and was assesed by paramedics.  The patient stated she felt better and her skin signs became normal. AMR 235 arrived on scene and was cancelled after pt refused transport.  did the AMA. Nurse did the asessment and paperwork.  Pt stated she had diarhea in the morning.  CAD #2021-00012425.
The evening after the first COVID vaccine dose, my sister noticed dark stained vaginal discharge, resembling beginning or late stages of the menstrual cycle. This continued for 2-3 days; with dark clots, with every wiping, and on underwear. Her menstrual cycle had finished for 8-9 days.
My daughter is having severe melt downs. She is very fussy and throwing tantrums. She yells and cries until she vomits. She is also having headache, abdominal pain. She wakes up in the middle of the night with acid reflex. She is not eating well. All this syntoms appeared 7 days after she got the MMR vaccine.
began having itching from abdomen up to neck and head and arms, took Benadryl, slept and felt better within 24 hours
Within one minute of vaccine administration the client stated he felt lightheaded and "faint". Lead RN called EMT over to assist. Client became unresponsive while sitting in the vaccination chair at approximately 1151. Client regained responsiveness in less than 10 seconds and was A&Ox4. Client denied any pertinent medical history and regular medication use. Client stated he was allergic to cephalexin but denied any other allergies to medications/food/environment. A first set of vitals were taken at 1152 BP: 120/80, HR: 60, RR 12, skins pale, cool and clammy. Client was sweating profusely and stated he felt nauseous at a level 1/10. Client stated his last oral intake was at 0930 when he had eggs for breakfast. Client was given a Nutrigrain bar and bottle of water and instructed to slip slowly and eat slowly. Client stated he had a "severe aversion" to needles. Client was transferred to a wheelchair and then the zero gravity chair in the observation area without incidence. A second set of vitals taken at 1200:  BP 122/80, HR: 70, RR 20, skins normal color for ethnicity, cool and clammy, A&Ox4. Client instructed to rest and relax in zero gravity chair for continued monitoring. At 1205 a third set of vitals taken: BP 132/90, HR 62, RR 18, skins normal color for ethnicity, warm and dry. Client stated he felt, "much better". He stated he felt, "a little weak, but the lightheadedness was gone". At 1220 a fourth set of vitals taken: BP 134/88, HR 60, RR 14, A&Ox4, skins warm, dry and normal color for ethnicity. Client stated he still felt a little weak but otherwise was fine. At 1245 client stated he felt ready to leave. A final set of vitals were taken at 1245 BP: 134/82, HR 60, RR 16 skins warm and dry. Lead RN educated client on ED precautions. At 1250 client left the observation site on his own accord and with a steady gait.
body aches; low grade fever of 100.6 degrees Fahrenheit; sore injection site; A spontaneous report was received from a 45-year-old, female consumer who was a nurse. The patient was participating in the mRNA-1273 Emergency Use Program and experienced the events of sore injection site, body aches and low-grade fever of 100.6 degrees Fahrenheit.   The patient's medical history included COVID-19. No concomitant medications were reported.  Prior to the onset of symptoms, the patient received their first of two planned doses of mRNA-1273 (lot #011J20A) intramuscularly in her left arm for prophylaxis of COVID-19 infection on 22 Dec 2020.   On 22 Dec 2020, the patient experienced sore injection site.  On 23 Dec 2020, the patient experienced body aches and low-grade fever of 100.6 degrees Fahrenheit. No other side effects were reported. Treatment for the events included, paracetamol and naproxen.   The action taken with mRNA-1273 in response to the events was not reported.   The outcome for the events, sore injection site, body aches and low-grade fever of 100.6 degrees Fahrenheit were unknown.  The reporter did not provide any assessment for the events.; Reporter's Comments: This case concerns a 45-year-old female patient with a medical history of COVID-19, who experienced the events of Pain, Injection site pain, and Pyrexia. Injection site pain occurred on the same day when the first dose of mRNA-1273 vaccine was administered. Pain and Pyrexia occurred the day after the first dose of mRNA-1273 vaccine. Based on the temporal association, the events are assessed as possibly related to mRNA-1273 vaccine.
not feeling well; Spikevax is the patient 6th dose. She had sore arm like she always has, and her stomach is hurting.; stomach is hurting; Patient had a lot of diarrheas all night.; Patient is tired; This spontaneous case was reported by a patient and describes the occurrence of MALAISE (not feeling well), PAIN IN EXTREMITY (Spikevax is the patient 6th dose. She had sore arm like she always has, and her stomach is hurting.), ABDOMINAL PAIN UPPER (stomach is hurting), DIARRHOEA (Patient had a lot of diarrheas all night.) and FATIGUE (Patient is tired) in an adult female patient who received mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (batch no. 3030535) for COVID-19 prophylaxis.     Patient did not had any medical history or condition.  Previously administered products included for Product used for unknown indication: Flu vaccine in October 2023. Past adverse reactions to the above products included No adverse event with Flu vaccine.    On 31-Oct-2023, the patient received sixth dose of mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (unknown route) 1 dosage form. On 31-Oct-2023, the patient experienced MALAISE (not feeling well), PAIN IN EXTREMITY (Spikevax is the patient 6th dose. She had sore arm like she always has, and her stomach is hurting.), ABDOMINAL PAIN UPPER (stomach is hurting), DIARRHOEA (Patient had a lot of diarrheas all night.) and FATIGUE (Patient is tired). At the time of the report, MALAISE (not feeling well), PAIN IN EXTREMITY (Spikevax is the patient 6th dose. She had sore arm like she always has, and her stomach is hurting.), ABDOMINAL PAIN UPPER (stomach is hurting) and FATIGUE (Patient is tired) was resolving and DIARRHOEA (Patient had a lot of diarrheas all night.) had resolved.        For mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (Unknown), the reporter did not provide any causality assessments.   The patient had received other vaccines in the 4 weeks prior to COVID-19 vaccine. The dosage text was reported as unknown. No concomitant medication was reported. The patient never had any side effects like this with the other vaccine. Except sore arm. The patient had sore arm like she always has, and the stomach was hurting. Patient had a lot of diarrheas all night. Now it had stop. Patient was not feeling well. Patient was tired. Patient was feeling better but still not feeling great. No treatment medication was reported.   This case was linked to MOD-2023-748086 (Patient Link).
The patient experienced no symptoms.; on 4/24/2020 a patient was administered a dose of improperly stored Varivax; This spontaneous report was received from a nurse referring to a patient of unknown age and gender. The patient's concurrent conditions, pertinent medical history, drug allergies/reactions and concomitant medications were not provided.  On 24-APR-2020, the patient was administered a dose of improperly stored varicella virus vaccine live (Oka/Merck) (VARIVAX) (lot# S028920, expiration date 16-SEP-2021, strength and dose were not provided) subcutaneously for prophylaxis. The Merck sterile diluent (lot # and expiration date were unknown) used for administration was properly stored.  The improperly stored of varicella virus vaccine live (Oka/Merck) (VARIVAX) experienced a temperature of -8.1 degree Celsius for 1 hour and 30 minutes. There was no previous temperature excursion reported. The digital data logger was involved. The patient experienced no symptoms.
dose was prepared incorrectly. only 0.8mL of normal saline was added to the vial and patient received 0.3mL IM.
Dehydration; Stomach pain; Apatite; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of DEHYDRATION (Dehydration) and ABDOMINAL PAIN UPPER (Stomach pain) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Multiple sclerosis (The patient was hospitalized before due to the Multiple Sclerosis so many time.) since March 2021.   On 09-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Apr-2021, the patient experienced DEHYDRATION (Dehydration) (seriousness criterion hospitalization), ABDOMINAL PAIN UPPER (Stomach pain) (seriousness criterion hospitalization) and APPETITE DISORDER (Apatite). On 14-Apr-2021, ABDOMINAL PAIN UPPER (Stomach pain) outcome was unknown. At the time of the report, DEHYDRATION (Dehydration) and APPETITE DISORDER (Apatite) outcome was unknown.       The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.    Reporter did not allow further contact
5 hours after vaccine started with body aches; then developed fever; next day adenopathy; fever fatigue; day 3 came to er with headache; lymphadenopathy; subjective fever
Itchy red spot on injection site; Itchy red spot on injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (Itchy red spot on injection site) and VACCINATION SITE ERYTHEMA (Itchy red spot on injection site) in an 85-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Mar-2021, the patient experienced VACCINATION SITE PRURITUS (Itchy red spot on injection site). 22-Mar-2021, the patient experienced VACCINATION SITE ERYTHEMA (Itchy red spot on injection site). The patient was treated with HYDROCORTISONE at an unspecified dose and frequency. At the time of the report, VACCINATION SITE PRURITUS (Itchy red spot on injection site) and VACCINATION SITE ERYTHEMA (Itchy red spot on injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       concomitant medicines was not reported by reporter   treatment information was not provide  For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Swelling (Edema, edema)(Edema) - recovered/resolved Redness (Rash, rash)(Rash) - recovered/resolved Warmth (Vasodilatation, Vasodilatation)(Vasodilat) - recovered/resolved Pain (Pain, Pain)(Pain) - recovered/resolved A report was received from an office manager on 11 November 2003 concerning a female vaccinee in her 30's who experienced swelling, redness, warmth and pain on the same day as receiving Fluvirin on 10 November 2003. On 10 November 2003 the vaccinee experienced swelling, redness, warmth and pain. The pain had been becoming milder at the time of the report. The vaccinee had not recovered at the time of the report. Update 1. 25 November 2003: Further information was recevied from an office manager on 25 November 2003 indicating that the swelling, redness, warmth and pain experienced by the 39 year old female vaccinee resolved 3 days after onset, on 13 November 2003. There was insufficient information to determine the reporter's causalty assessment. No follow-up pending.
CHILD WAS CRYING VERY HARD JUST BEFORE VACCINE ADMINISTRATION. PERSPIRING AND JUMPING ON MOM'S LAP.  REFUSED TO BE CONSOLED AT THIS TIME. H1N1 VACCINE WAS ADM. INTRANASALLY.  AFTER BEING ADMINISTERED VACCINE CHILD CONTINUED TO CRY AND WAS INCONSOLABLE. PERSPIRING AND UPSET. AT APPROX 6:33 NOTED A STREAM OF BLOOD COMING FROM RT. NOSTRIL. MOM WIPED CHILD NOSE AND HELD HER ON HER LAP TO CONSOLE AND QUIET HER.  REQUESTED THAT THE CHILD REMAIN IN THE CLINIC FOR OBSERVATION FOR A APPROX. 15-30 MIN. AT 7:45PM CHILD WAS QUIET AND NO FURTHER BLEEDING EPISODES. I DID NOTE CHILD PICKED HER NOSE WHEN FIRST ENTERING THE THE TREATMENT ROOM. FAMILY ALLOWED TO LEAVE THE CLINIC. A CALL TO FAMILY ON 11/10/09 TO ENQUIRE ABOUT NOSE BLEED NO ANSWER TO PHONE. I LEFT A MESSAGE ON ANSWERING MACHINE FOR MOM TO CALL ME AND ASKED ABOUT FURTHER EPISODES OF NOSE BLEEDING.  I WILL FOLLOW UP CALL IN A DAY OR TWO IF NO ANSWER.
Her arm itched as it does every year, but this time - 4 days after the immunization, her arm had a huge red welt from shoulder to elbow. It resolved with Hydrocortisone cream.
My symptoms started  on 10/08/2022 at  lunch  time around 12:00PM - 12:30PM .  I ate fresh tomatoes for lunch as soon as  I ate it my throat started hurting . I had a bad headache,  fever, my neck was hurting, my rib cage was hurting, dizziness,  sneezing, runny nose, exhausted, tiredness,  and weakness. I took a test on 10/08/2022 it was negative. I did another test on 10/09/2022  Sunday it was positive.   On 10/09/2022 I did a tele health with a Nurse she prescribed me with  Tylenol, and  Flonase. she also told me to take Paxlovid but I choose not to take it. As of today 10/11/2022 I am recovering from COVID-19.
This case was reported by a pharmacist via call center representative and described the occurrence of pain in arm in a 76-year-old female patient who received SHINGRIX (batch number 79N59, expiry date March 2019). On an unknown date, the patient received SHINGRIX (subcutaneous). On an unknown date, unknown after receiving SHINGRIX, the patient experienced intramuscular formulation administered by other route. On an unknown date, the outcome of the intramuscular formulation administered by other route was unknown. Additional details were provided as follows: The age at vaccination was not reported. The healthcare professional reported that the patient inadvertently received a dose of SHINGRIX via subcutaneous route, which led to inappropriate route vaccine administration. No further information reported regarding the event. Follow up information received from pharmacist 20th April 2018: The patient details were updated. On 16th March 2018, the patient received 1st dose of SHINGRIX. In March 2018, less than a week after receiving SHINGRIX, the patient experienced pain in arm and the pain in arm which was lasted for 1 to 2 days. It was unknown if the reporter considered the pain in arm to be related to SHINGRIX. The VAERS details were updated. This was a medication error associated with adverse event.
Patient received a Pfizer Monovalent booster instead of a bivalent booster.  Patient's dad informed of the immunization error. Dad states patient did not have an adverse reaction to the vaccine.
When I got the shot on Wednesday, September 29th, it was much more painful than either of my two Pfizer COVID-19 shots or my Flu shot. I flexed my arm for several minutes to move the vaccine through the muscle faster. I?ve reduced injection pain that way in the past. That evening my arm was sore, but that was not unexpected. The next day, Thursday, September 30th, I realized my arm was unexpectedly quite sore, not only to the touch, but also when I lifted my arm or flexed my deltoid where I had got the injection. The next day, Friday, October 1st, in the morning, I noticed that the site of my injection was reddened in a patch about 4 cm  up and down and 7 cm in width across my arm. That area was also slightly swollen, and was quite painful to the touch, and felt quite a bit warmer than the rest of my Arm. I had not looked closely at my arm the previous day, so I don?t know if this reaction (the redness and swelling) was apparent on Thursday, September 30th. I felt this was probably what had been described on the vaccine information statement given to me at the time of my vaccine.  To my surprise, the redness and swelling, as well as the tenderness/soreness lasted throughout Saturday, October 2nd. Today, October 3rd, the swelling is down and most of the redness has faded. It?s still slightly tender, but no where near the tenderness the previous days.  It does not feel warmer to the touch, but my perception is that I can feel warmth inside my arm in a very unusual way. I feel that this reaction is outside the norm.